This podcast series from the Academy's Committee on Aging features leading experts who discuss clinical experiences and the differences in caring for older adults.

In today’s podcast, Dr. Charles Wykoff discusses his approach to patients with neovascular age-related macular degeneration (AMD), weighing the latest trial outcomes that compare the various anti-VEGF agents and treatment protocols. If cost is no barrier, which agent should you initiate first: aflibercept, ranibizumab, or bevacizumab? How often should you see and treat a patient once all subretinal fluid has resolved and visual acuity is stable? Is a treat-and-extend regimen as effective and proven as PRN? How do you approach a patient who no longer responds to therapy, or when fluid resumes? Dr. Wykoff shares his preferred strategies and explains the challenges in planning long-term care for patients with exudative AMD.

  Funded in part by the Retina Research Foundation